This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose
escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of
SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be
evaluated and this study will provide the recommended dosage for subsequent clinical trials.